Dapagliflozin

Overview

Dapagliflozin is a sodium-glucose cotransporter 2 inhibitor used to manage type 2 diabetes mellitus. It helps improve glycemic control and has cardiovascular benefits.

API suppliers (4)

Suppliers of Dapagliflozin backed by a verifiable FDA Type II Drug Master File. Source: FDA quarterly DMF list.

• Zakłady Farmaceutyczne Polpharma S.A.Poland1 active DMF
• BioPharma, Inc.United States1 active DMF
• MICRO LABS LTDIndia1 active DMF
• HARMAN FINOCHEM LTD1 active DMF

Patent & exclusivity (US)

Per the FDA Orange Book (32 approved US products), the latest listed US patent on Dapagliflozin expires 30 Sept 2041 and exclusivity 12 Dec 2027. Generic API sourcing typically opens up once these lapse.

Therapeutic areas